DMIIR · Drugs Made In America Acquisition II Corp. · Executive Compensation
$0.07
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
Market Cap
$649.42M
Shares
63.70M
Volume · Oct 27
18.2K
Avg daily vol (3M)
24.86K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Roger Bendelac | Chief Executive Officer | Appointed | 2026-03-06 |
| Lynn Stockwell | member of the Board | Terminated | 2026-03-06 |
| Lynn Stockwell | Executive Chair of the Board | Terminated | 2026-03-06 |
| Lynn Stockwell | Chief Executive Officer | Terminated | 2026-03-06 |
| Lynn Stockwell | member of the Board | Resigned | 2026-03-06 |
| Lynn Stockwell | Executive Chair of the Board | Resigned | 2026-03-06 |
| Lynn Stockwell | Chief Executive Officer | Resigned | 2026-03-06 |
| Saleem Elmasri | principal financial and accounting officer | Appointed | 2025-11-18 |
| Saleem Elmasri | Chief Financial Officer | Appointed | 2025-11-18 |
| Glenn Worman | principal financial and accounting officer | Resigned | 2025-11-18 |
| Glenn Worman | Chief Financial Officer and principal financial and accounting officer | Resigned | 2025-11-18 |
| G. Sridhar Prasad | director | Appointed | 2025-09-29 |
| Myron W. Shulgan | director | Appointed | 2025-09-29 |
| Catherine Do | director | Appointed | 2025-09-29 |
Leadership
- Roger Bendelac CEO
- Saleem Elmasri CFO, Chief Accounting Officer
- Catherine Do Board Member
- G. Sridhar Prasad Board Member
- Myron W. Shulgan Board Member
Key facts
CIK
2040475
CUSIP
G2851K104
13F (30d)
1 filings
1 filers